IZEA +64% A nanocap adtech company. Came out with a new 3d sponsorship product.
MDGL +53% Ini from Evercore with a $65 PT. $400M market cap, a decent sized small cap biotech. What really moved it is the $300 PT bull case that Evercore put on it. That's what really impressed investors. Is it possible that investors really missed this stock by that much?
But I see this stock fading on Monday, people just don't beleive those kind of PTs, and it has a 52 week low of $11.25, quite a bit lower than its close of $34.18. It didn't rise very much on ph 2 positive data. The stock will pop at the open, and then sell off by the close is my prediction.
ARDM +29% No apparent news causing the rally. Could it be from anticipation of the Ladenburg Thalmann conference presentation on Tuesday afternoon?
SSC +27% Microcap, B2B virtual platform in China. Has some fancy buzzwords to describe itself, like AI. Chinese stocks don't need US news to move far.
ASND +23% As mentioned earlier, just because its competitor's competing drug failed, doesn't mean this drug won't. Also, a very good analyst at Wells, which I checked on Tipranks.com, said this was a positive, but he didn't increase his price target on ASND. ASND was up 50% in the PM, was a good fade opp for these reasons.
ALPN +19% Ug to buy from hold at Stifel. Has come down a lot since its 52 week high. Collaboration with Kite is a strong positive.
HMNY +19% Up on interview with executive. Doesn't seem like a good model, because the more times people use it, the more money the company loses. With Netflix or a gym, more people can use it and it won't cost the company much more.
QUAD +14% Likely delayed reaction to news that it was awarded a $450M contract announced Thursday afternoon.
BEDU +14% A chinese private school company. No news.
OMNT +14% Company hasn't been in compliance with NASDAQ listing requirements. The stock has been getting crushed, this is likely an empty bounce.
VSAR -87% Phase 3 trial of growth hormone drug missed primary endpoint.
RVLT -17% Down on bad earnings and guidance.
ICPT -16% The dangers of the drug exposed, down huge today after being down huge yesterday as analysts submit negative opinion.
CMP -14% Lowered guidance.
EXEL -13% Leerink dg to market perform from op, says stock is fairly valued. Believes commercial opp is smaller than anticipated.
TYHT -12% Down on news of strategic collaboration. Not sure why, is a health supplement Chinese company microcap.
NXTD -11% A nanocap cybersecurity stock. No news.
LTEA -10% Nanocap tea company. On a continued multi-month downtrend.
VSLR -9% No news. An unprofitable company like SCTY. Could have problems down the road.
EPZM -9% Retraced a recent multi-day rally. Gave it all back.